1379453-67-4

Basic information

• Product Name: 2-ethylthio-6-benzylamino-9-β-D-ribofuranosyl purine
• Synonyms: 2-ethylthio-6-benzylamino-9-β-D-ribofuranosyl purine
• CAS NO: 1379453-67-4
• Molecular Weight: 417.489
• Mol File: 1379453-67-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-ethylthio-6-benzylamino-9-β-D-ribofuranosyl purine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-ethylthio-6-benzylamino-9-β-D-ribofuranosyl purine(1379453-67-4)
• EPA Substance Registry System: 2-ethylthio-6-benzylamino-9-β-D-ribofuranosyl purine(1379453-67-4)

Safety Data

• Hazardous Substances Data: 1379453-67-4(Hazardous Substances Data)

Upstream product

• 221552-84-7 6-chloro-2-ethylthio-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine 
• 6979-94-8 2',3',5'-tri-O-acetyl-guanosine 
• 118-00-3 G 
• 16321-99-6 2-amino-6-chloro-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)purine 

Relevant articles and documents

Essential Structural Profile of Novel Adenosine Derivatives as Antiplatelet Aggregation Inhibitors Based on 3D-QSAR Analysis Using CoMFA, CoMSIA, and SOMFA

Abstact: —In this study, comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA), and the self-organizing molecular field analysis (SOMFA) were performed on a series of novel adenosine derivatives. Significant correlation coefficients (CoMFA, q2 = 0.560, r2 = 0.940, F value = 71.850, and SEE = 0.097; CoMSIA, q2 = 0.528, r2 = 0.943, F value = 29.29 and SEE = 0.108; SOMFA, r2 = 0.615, r2cr= 0.577, F value = 60.797, and SEE = 0.226) were obtained, and the generated models were validated using test sets. By analyzing the corresponding contour maps in detail, new adenosine derivatives with potential efficacy were designed for synthesis in the future.

RIBOFURANOSYL PURINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF

The present invention relates to the compounds of the formulae (I) and (I-1) and the process for preparing the same, uses of the compounds for the treatment of diseases associated with platelet aggregation and in the manufacture of a medicament for the treatment of diseases associated with platelet aggregation, and relates to a pharmaceutical composition and a pharmaceutical formulation containing the compounds, wherein the definitions of R1, R2, R3 and R2a in the formulae are the same as those in the description.